Amprya Bioequivalent Approved for Multiple Sclerosis

Article

Dalfampridine extended-release tablets deemed bioequivalent of Amprya.

The FDA has given final approval to Aurobindo Pharma Limited for dalfampridine extended-release tablets (10-mg). The agency’s Division of Bioequivalence determined the product is the bioequivalent of Amprya from Acorda Therapeutics, and it is indicated for the treatment of multiple sclerosis (MS).

Amprya’s main ingredient is dalfampridine, which works to block potassium channels in the body. In turn, MS patients may see an improvement in walking and an increase in walking speed.

The most common adverse effects associated with Amprya are urinary tract infection, insomnia, dizziness, headache, nausea, weakness, and back pain.

The drug may cause seizures in some patients. In studies, those who used 20-mg of Amprya twice daily showed an increased incidence of seizures. The drug has not been studied in patients with a history of seizures.

Aurobindo’s product portfolio now consists of 256 final approvals, including 39 tentative approvals and 16 approved products from Aurolife.

The FDA has given final approval to Aurobindo Pharma Limited for dalfampridine extended-release tablets (10-mg). The agency’s Division of Bioequivalence determined the product is the bioequivalent of Amprya from Acorda Therapeutics, and it is indicated for the treatment of multiple sclerosis (MS).

Amprya’s main ingredient is dalfampridine, which works to block potassium channels in the body. In turn, MS patients may see an improvement in walking and an increase in walking speed.

The most common adverse effects associated with Amprya are urinary tract infection, insomnia, dizziness, headache, nausea, weakness, and back pain.

The drug may cause seizures in some patients. In studies, those who used 20-mg of Amprya twice daily showed an increased incidence of seizures. The drug has not been studied in patients with a history of seizures.

Aurobindo’s product portfolio now consists of 256 final approvals, including 39 tentative approvals and 16 approved products from Aurolife.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.